Report

TABLE OF CONTENTS
1 INTRODUCTION 202
1.1 OBJECTIVES OF THE STUDY 202
1.2 MARKET DEFINITION 202
1.3 OVERVIEW OF EUROPE AESTHETIC INJECTABLE FILLERS MARKET 202
1.4 LIMITATIONS 205
1.5 MARKETS COVERED 205
2 MARKET SEGMENTATION 214
2.1 MARKETS COVERED 214
2.2 GEOGRAPHICAL SCOPE 215
2.3 YEARS CONSIDERED FOR THE STUDY 216
2.4 CURRENCY AND PRICING 216
2.5 DBMR TRIPOD DATA VALIDATION MODEL 217
2.6 MULTIVARIATE MODELLING 220
2.7 PRODUCT TYPE LIFELINE CURVE 220
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 221
2.9 DBMR MARKET POSITION GRID 222
2.10 MARKET END USER COVERAGE GRID 223
2.11 VENDOR SHARE ANALYSIS 224
2.12 SECONDARY SOURCES 225
2.13 ASSUMPTIONS 225
3 EXECUTIVE SUMMARY 226
4 PREMIUM INSIGHTS 233
4.1 PORTER'S FIVE FORCES 234
4.1.1 COMPETITIVE RIVALRY - HIGH 234
4.1.2 THREAT OF NEW ENTRANTS - MODERATE 234
4.1.3 BARGAINING POWER OF BUYERS - HIGH 235
4.1.4 BARGAINING POWER OF SUPPLIERS - MODERATE 235
4.1.5 THREAT OF SUBSTITUTES - MODERATE 235
4.2 PESTLE ANALYSIS 236
4.2.1 POLITICAL 236
4.2.2 ECONOMIC 236
4.2.3 SOCIAL 236
4.2.4 TECHNOLOGICAL 237
4.2.5 ENVIRONMENTAL 237
4.2.6 LEGAL 237
4.3 COST ANALYSIS BREAKDOWN 238
4.3.1 RESEARCH & DEVELOPMENT (R&D) COSTS (15-25%) 238
4.3.2 RAW MATERIAL AND COMPONENT COSTS (20-30%) 238
4.3.3 MANUFACTURING COSTS (15-20%) 238
4.3.4 REGULATORY & QUALITY COMPLIANCE (5-10%) 238
4.3.5 MARKETING & PROMOTION (10-15%) 238
4.3.6 DISTRIBUTION & LOGISTICS (5-10%) 238
4.3.7 LICENSING, ROYALTIES & IP MANAGEMENT (1-3%) 238
4.3.8 TRAINING, CLINICAL SUPPORT & AFTER-SALES (2-5%) 238
4.4 HEALTHCARE ECONOMY 239
4.4.1 HEALTHCARE EXPENDITURE 239
4.4.2 CAPITAL EXPENDITURE 239
4.4.3 CAPEX TRENDS 239
4.4.4 CAPEX ALLOCATION 239
4.4.5 FUNDING SOURCES 239
4.4.6 INDUSTRY BENCHMARKS 240
4.4.7 GDP RATIO IN OVERALL GDP 240
4.4.8 HEALTHCARE SYSTEM STRUCTURE 240
4.4.9 GOVERNMENT POLICIES 240
4.4.10 ECONOMIC DEVELOPMENT 241
4.5 OPPORTUNITY MAP ANALYSIS 242
4.5.1 OPPORTUNITY MAP ANALYSIS 242
4.5.2 PRODUCT INNOVATION 242
4.5.3 GEOGRAPHIC EXPANSION 242
4.5.4 CONSUMER SEGMENTATION 242
4.5.5 DELIVERY CHANNELS 242
4.5.6 REGULATORY & MARKET ACCESS 243
4.5.7 SUSTAINABILITY 243
4.6 INDUSTRY INSIGHTS 244
4.6.1 MICRO AND MACRO ECONOMIC FACTORS 244
4.6.2 PENETRATION AND GROWTH PROSPECT MAPPING 244
4.6.3 KEY PRICING STRATEGIES 244
4.6.4 INTERVIEWS WITH SPECIALISTS 244
4.6.5 ANALYSIS AND RECOMMENDATION 244
4.7 PATENT ANALYSIS- 245
4.7.1 GEOGRAPHIC DISTRIBUTION OF PATENT FILINGS 245
4.7.2 KEY APPLICANTS AND INNOVATORS 246
4.7.3 TECHNOLOGICAL DOMAINS (IPC CODES) 247
4.8 PUBLICATION TRENDS OVER TIME 248
4.8.1 CONCLUSION 248
4.9 EIMBURSEMENT FRAMEWORK 249
4.9.1 COSMETIC VS. MEDICAL USE - THE CORE DIVIDER 249
4.9.2 REGIONAL REIMBURSEMENT VARIATIONS 249
4.9.3 OUT-OF-POCKET SPENDING DOMINANCE 250
4.9.4 TRENDS IN HYBRID INSURANCE MODELS 250
4.9.5 IMPLICATIONS FOR MARKET GROWTH 250
4.10 SUPPLY CHAIN ECOSYSTEM 251
4.11 TECHNOLOGY ROADMAP 252
4.12 INNOVATION TRACKER AND STRATEGIC ANALYSIS 254
4.12.1 INNOVATION TRACKER 254
4.12.1.1 Bio-Remodeling & Platform Technologies 254
4.12.1.2 Smart Filler Design & Volume Efficiency 254
4.12.1.3 Next-Generation Delivery Systems 254
4.12.1.4 Green Chemistry and Bioplastics 254
4.12.1.5 Combination Modalities 254
4.12.2 STRATEGIC ANALYSIS 254
4.12.2.1 M&A and Market Consolidation 254
4.12.2.2 Geographical Expansion & Localization Strategies 255
4.12.2.3 Regulatory Milestones 255
4.12.2.4 Marketing & Consumer Engagement 255
4.12.2.5 Strategic Partnerships & Distribution Rights 255
4.12.3 CONCLUSION 255
5 CURRENT TARIFF RATES IN TOP-5 COUNTRY MARKETS AND IMPORT VS. LOCAL PRODUCTION OUTLOOK 256
5.1 VENDOR SELECTION CRITERIA AND ITS IMPACT ON THE SUPPLY CHAIN 256
5.2 RAW MATERIAL PROCUREMENT, MANUFACTURING, AND DISTRIBUTION DYNAMICS 256
5.3 PRICE PITCHING AND COMPETITIVE POSITIONING IN THE MARKET 257
5.4 INDUSTRY RESPONSE: SUPPLY CHAIN OPTIMIZATION AND JOINT VENTURES 257
5.5 IMPACT OF REGULATORY FRAMEWORKS AND INCENTIVES ON PRICES 257
5.6 GEOPOLITICAL FACTORS AND TRADE AGREEMENTS SHAPING THE MARKET 258
5.7 INDUSTRIAL DEVELOPMENT SCHEMES AND INFRASTRUCTURE INITIATIVES 258
6 REGULATORY FRAMEWORK 259
6.1 NORTH AMERICA 259
6.1.1 REGULATORY AUTHORITIES: 259
6.1.2 REGULATORY CLASSIFICATIONS: 259
6.1.3 REGULATORY SUBMISSIONS: 260
6.1.4 INTERNATIONAL HARMONIZATION: 260
6.1.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS: 260
6.2 SOUTH AMERICA 260
6.2.1 REGULATORY AUTHORITIES: 260
6.2.2 REGULATORY CLASSIFICATIONS: 260
6.2.3 REGULATORY SUBMISSIONS: 260
6.2.4 INTERNATIONAL HARMONIZATION: 260
6.2.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS: 261
6.2.6 REGULATORY CHALLENGES AND STRATEGIES: 261
6.3 EUROPE 261
6.3.1 REGULATORY AUTHORITIES: 261
6.3.2 REGULATORY CLASSIFICATIONS: 261
6.3.3 REGULATORY SUBMISSIONS: 261
6.3.4 INTERNATIONAL HARMONIZATION: 261
6.3.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS: 261
6.3.6 REGULATORY CHALLENGES AND STRATEGIES: 261
6.4 ASIA-PACIFIC 262
6.4.1 REGULATORY AUTHORITIES: 262
6.4.2 REGULATORY CLASSIFICATIONS: 262
6.4.3 REGULATORY SUBMISSIONS: 262
6.4.4 INTERNATIONAL HARMONIZATION: 262
6.4.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS: 262
6.4.6 REGULATORY CHALLENGES AND STRATEGIES: 262
6.5 MIDDLE EAST AND AFRICA 262
6.5.1 REGULATORY AUTHORITIES: 262
6.5.2 REGULATORY CLASSIFICATIONS: 262
6.5.3 REGULATORY SUBMISSIONS: 262
6.5.4 INTERNATIONAL HARMONIZATION: 262
6.5.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS: 263
6.5.6 REGULATORY CHALLENGES AND STRATEGIES: 263
7 MARKET OVERVIEW 264
7.1 DRIVERS 266
7.1.1 GROWING DEMAND FOR MINIMALLY INVASIVE COSMETIC PROCEDURES 266
7.1.2 RISING INFLUENCE OF SOCIAL MEDIA AND CELEBRITY CULTURE 267
7.1.3 INCREASING ACCEPTANCE OF COSMETIC ENHANCEMENTS AMONG MILLENNIALS AND GEN Z 268
7.1.4 RISING POPULARITY OF COMBINATION TREATMENTS 269
7.2 RESTRAINTS 271
7.2.1 HIGH COST OF AESTHETIC INJECTABLE PROCEDURES 271
7.2.2 SHORT-TERM EFFECTIVENESS OF CERTAIN FILLERS 272
7.3 OPPORTUNITIES 273
7.3.1 EXPANSION IN EMERGING MARKETS 273
7.3.2 PRODUCT INNOVATION AND PERSONALIZED SOLUTIONS 274
7.3.3 BROADENING INTO ADDITIONAL THERAPEUTIC AREAS 275
7.4 CHALLENGES 276
7.4.1 LACK OF SKILLED PROFESSIONALS IN CERTAIN REGIONS 276
7.4.2 COUNTERFEIT AND UNREGULATED PRODUCTS 277
8 EUROPE AESTHETIC INJECTABLE FILLERS MARKET, BY TYPE 279
8.1 OVERVIEW 280
8.2 BIODEGRADABLE AESTHETIC INJECTABLE FILLERS 284
8.2.1 TEMPORARY BIODEGRADABLE 285
8.2.2 SEMI-PERMANENT BIODEGRADABLE 285
8.3 NON-BIODEGRADABLE AESTHETIC INJECTABLE FILLERS 286
9 EUROPE AESTHETIC INJECTABLE FILLERS MARKET, BY PRODUCT TYPE 287
9.1 OVERVIEW 288
9.2 NATURAL AESTHETIC INJECTABLE FILLERS 292
9.2.1 HYALURONIC ACID (HA) 293
9.2.1.1 MONOPHASIC FILLERS 294
9.2.1.1.1 HYALURONIC ACID + LIDOCAINE 294
9.2.1.1.2 MONODENSIFIED 294
9.2.1.1.3 POLYDENSIFIES 295
9.2.1.1.4 FACIAL LINE CORRECTION 296
9.2.1.1.5 LIP ENHANCEMENT 296
9.2.1.1.6 FACE LIFT 296
9.2.1.1.7 RHINOPLASTY 296
9.2.1.1.8 SCAR TREATMENT 296
9.2.1.1.9 SAGGING SKIN 296
9.2.1.1.10 CHEEK DEPRESSION 296
9.2.1.1.11 DENTISTRY 296
9.2.1.1.12 RECONSTRUCTIVE SURGERY 296
9.2.1.1.13 AESTHETIC RESTORATION 296
9.2.1.1.14 CHIN AUGMENTATION 296
9.2.1.1.15 LIPOATROPHY TREATMENT 296
9.2.1.1.16 SKIN SMOOTHING 296
9.2.1.1.17 EARLOBE REJUVENATION 296
9.2.1.1.18 OTHERS. 296
9.2.1.2 BIPHASIC FILLERS 297
9.2.1.2.1 HYALURONIC ACID + LIDOCAINE 297
9.2.1.2.2 SINGLE-PHASE 297
9.2.1.2.3 DUPLEX-PHASE 298
9.2.1.2.4 FACIAL LINE CORRECTION 299
9.2.1.2.5 LIP ENHANCEMENT 299
9.2.1.2.6 FACE LIFT 299
9.2.1.2.7 RHINOPLASTY 299
9.2.1.2.8 SCAR TREATMENT 299
9.2.1.2.9 SAGGING SKIN 299
9.2.1.2.10 CHEEK DEPRESSION 299
9.2.1.2.11 DENTISTRY 299
9.2.1.2.12 RECONSTRUCTIVE SURGERY 299
9.2.1.2.13 AESTHETIC RESTORATION 299
9.2.1.2.14 CHIN AUGMENTATION 299
9.2.1.2.15 LIPOATROPHY TREATMENT 299
9.2.1.2.16 SKIN SMOOTHING 299
9.2.1.2.17 EARLOBE REJUVENATION 299
9.2.1.2.18 OTHERS 299
9.2.2 FAT 300
9.2.2.1 FACIAL LINE CORRECTION 301
9.2.2.2 LIP ENHANCEMENT 301
9.2.2.3 FACE LIFT 301
9.2.2.4 RHINOPLASTY 301
9.2.2.5 SCAR TREATMENT 301
9.2.2.6 SAGGING SKIN 301
9.2.2.7 CHEEK DEPRESSION 301
9.2.2.8 RECONSTRUCTIVE SURGERY 301
9.2.2.9 DENTISTRY 301
9.2.2.10 AESTHETIC RESTORATION 301
9.2.2.11 LIPOATROPHY TREATMENT 301
9.2.2.12 CHIN AUGMENTATION 301
9.2.2.13 SKIN SMOOTHING 301
9.2.2.14 EARLOBE REJUVENATION 301
9.2.2.15 OTHERS 301
9.2.3 COLLAGEN 302
9.2.3.1 FACIAL LINE CORRECTION 303
9.2.3.2 LIP ENHANCEMENT 303
9.2.3.3 FACE LIFT 303
9.2.3.4 RHINOPLASTY 303
9.2.3.5 SCAR TREATMENT 303
9.2.3.6 SAGGING SKIN 303
9.2.3.7 CHEEK DEPRESSION 303
9.2.3.8 RECONSTRUCTIVE SURGERY 303
9.2.3.9 AESTHETIC RESTORATION 303
9.2.3.10 CHIN AUGMENTATION 303
9.2.3.11 DENTISTRY 303
9.2.3.12 LIPOATROPHY TREATMENT 303
9.2.3.13 SKIN SMOOTHING 303
9.2.3.14 EARLOBE REJUVENATION 303
9.2.3.15 OTHERS 303
9.2.4 POLYNUCLEOTIDES / POLYDEOXYRIBONUCLEOTIDES (PN/PDRN) 304
9.2.4.1 FACIAL LINE CORRECTION 305
9.2.4.2 LIP ENHANCEMENT 305
9.2.4.3 FACE LIFT 305
9.2.4.4 RHINOPLASTY 305
9.2.4.5 SCAR TREATMENT 305
9.2.4.6 SAGGING SKIN 305
9.2.4.7 CHEEK DEPRESSION 305
9.2.4.8 AESTHETIC RESTORATION 305
9.2.4.9 RECONSTRUCTIVE SURGERY 305
9.2.4.10 DENTISTRY 305
9.2.4.11 CHIN AUGMENTATION 305
9.2.4.12 LIPOATROPHY TREATMENT 305
9.2.4.13 SKIN SMOOTHING 305
9.2.4.14 EARLOBE REJUVENATION 305
9.2.4.15 OTHERS 305
9.2.5 OTHERS 306
9.2.5.1 FACIAL LINE CORRECTION 307
9.2.5.2 LIP ENHANCEMENT 307
9.2.5.3 FACE LIFT 307
9.2.5.4 RHINOPLASTY 307
9.2.5.5 SCAR TREATMENT 307
9.2.5.6 SAGGING SKIN 307
9.2.5.7 CHEEK DEPRESSION 307
9.2.5.8 RECONSTRUCTIVE SURGERY 307
9.2.5.9 AESTHETIC RESTORATION 307
9.2.5.10 DENTISTRY 307
9.2.5.11 CHIN AUGMENTATION 307
9.2.5.12 LIPOATROPHY TREATMENT 307
9.2.5.13 SKIN SMOOTHING 307
9.2.5.14 EARLOBE REJUVENATION 307
9.2.5.15 OTHERS 307
9.3 SYNTHETIC AESTHETIC INJECTABLE FILLERS 308
9.3.1 CALCIUM HYDROXYLAPATITE (CAHA) 310
9.3.1.1 FACIAL LINE CORRECTION 311
9.3.1.2 LIP ENHANCEMENT 311
9.3.1.3 FACE LIFT 311
9.3.1.4 RHINOPLASTY 311
9.3.1.5 SCAR TREATMENT 311
9.3.1.6 SAGGING SKIN 311
9.3.1.7 CHEEK DEPRESSION 311
9.3.1.8 RECONSTRUCTIVE SURGERY 311
9.3.1.9 AESTHETIC RESTORATION 311
9.3.1.10 DENTISTRY 311
9.3.1.11 CHIN AUGMENTATION 311
9.3.1.12 LIPOATROPHY TREATMENT 311
9.3.1.13 SKIN SMOOTHING 311
9.3.1.14 EARLOBE REJUVENATION 311
9.3.1.15 OTHERS 311
9.3.2 POLY-L-LACTIC ACID (PLLA) 312
9.3.2.1 FACIAL LINE CORRECTION 313
9.3.2.2 LIP ENHANCEMENT 313
9.3.2.3 FACE LIFT 313
9.3.2.4 RHINOPLASTY 313
9.3.2.5 SCAR TREATMENT 313
9.3.2.6 SAGGING SKIN 313
9.3.2.7 CHEEK DEPRESSION 313
9.3.2.8 RECONSTRUCTIVE SURGERY 313
9.3.2.9 AESTHETIC RESTORATION 313
9.3.2.10 DENTISTRY 313
9.3.2.11 CHIN AUGMENTATION 313
9.3.2.12 LIPOATROPHY TREATMENT 313
9.3.2.13 SKIN SMOOTHING 313
9.3.2.14 EARLOBE REJUVENATION 313
9.3.2.15 OTHERS 313
9.3.3 POLYMETHYL-METHACRYLATE MICROSPHERES (PMMA) 314
9.3.3.1 FACIAL LINE CORRECTION 315
9.3.3.2 LIP ENHANCEMENT 315
9.3.3.3 FACE LIFT 315
9.3.3.4 RHINOPLASTY 315
9.3.3.5 SCAR TREATMENT 315
9.3.3.6 SAGGING SKIN 315
9.3.3.7 CHEEK DEPRESSION 315
9.3.3.8 RECONSTRUCTIVE SURGERY 315
9.3.3.9 AESTHETIC RESTORATION 315
9.3.3.10 DENTISTRY 315
9.3.3.11 CHIN AUGMENTATION 315
9.3.3.12 LIPOATROPHY TREATMENT 315
9.3.3.13 SKIN SMOOTHING 315
9.3.3.14 EARLOBE REJUVENATION 315
9.3.3.15 OTHERS 315
10 EUROPE AESTHETIC INJECTABLE FILLERS MARKET, BY DRUG TYPE 316
10.1 OVERVIEW 317
10.2 BRANDED 320
10.2.1 JUVEDERM 321
10.2.2 RESTYLANE 321
10.2.3 RADIESSE 321
10.2.4 SCULPTRA 321
10.2.5 ELLANSE 321
10.2.6 BELLAFILL 321
10.2.7 AQUAMID 321
10.2.8 ELEVESS 321
10.2.9 OTHERS 321
10.3 GENERIC 322
11 EUROPE AESTHETIC INJECTABLE FILLERS MARKET, BY APPLICATION 323
11.1 OVERVIEW 324
11.2 FACIAL LINE CORRECTION 328
11.2.1 DYNAMIC WRINKLES 329
11.2.2 STATIC WRINKLES 329
11.2.3 WRINKLE FOLDS 329
11.2.4 LAUGH LINES 329
11.2.5 FOREHEAD LINES 329
11.2.6 WORRY LINES 329
11.2.7 CROW'S FEET 329
11.2.8 LIP LINES 329
11.2.9 MARIONETTE LINES 329
11.2.10 PUPPET WRINKLES 329
11.2.11 BUNNY LINES 329
11.2.12 OTHERS 330
11.2.13 JUVEDERM 330
11.2.14 RESTYLANE 330
11.2.15 BELOTERO 330
11.2.16 RADIESSE 330
11.2.17 OTHERS 330
11.3 LIP ENHANCEMENT 331
11.3.1 JUVEDERM 332
11.3.1.1 JUVEDERM XC 333
11.3.1.2 VOLUMA 333
11.3.1.3 VOLBELLA 333
11.3.1.4 VOLLURE 333
11.3.2 RESTYLANE 333
11.3.2.1 RESTYLANE LYFT 333
11.3.2.2 RESTYLANE KYSSE 333
11.3.2.3 RESTYLANE CONTOUR 333
11.3.2.4 RESTYLANE REFYNE 333
11.3.2.5 RESTYLANE SILK 333
11.3.3 BELOTERO BALANCE 334
11.3.4 RHA 334
11.3.4.1 RHA 2 334
11.3.4.2 RHA 3 334
11.3.4.3 RHA 4 334
11.3.5 REVANESSE VERSA 334
11.3.6 HYLAFORM 334
11.3.7 ELEVESS 334
11.3.8 PREVELLE SILK 334
11.3.9 OTHERS 334
11.4 FACE LIFT 335
11.4.1 DEEP PLANE/SMAS FACELIFT 336
11.4.2 MINI FACELIFT 336
11.4.3 MID-FACELIFT 336
11.4.4 LIQUID FACELIFT 336
11.4.5 CHEEK LIFT 336
11.4.6 JAW LINE REJUVENATION 336
11.4.7 S-LIFT 336
11.4.8 CUTANEOUS LIFT 336
11.4.9 TEMPORAL/BROW LIFT 336
11.4.10 OTHERS 337
11.4.11 JUVEDERM 337
11.4.12 RESTYLANE 337
11.4.13 SCULPTRA 337
11.4.14 DYSPORT 337
11.4.15 OTHERS 337
11.5 RHINOPLASTY 338
11.5.1 JUVEDERM 339
11.5.1.1 VOLUMA 340
11.5.1.2 VOLBELLA 340
11.5.1.3 JUVEDERM XC 340
11.5.1.4 VOLLURE 340
11.5.2 RESTYLANE 340
11.5.2.1 RESTYLANE LYFT 340
11.5.2.2 RESTYLANE SILK 340
11.5.2.3 RESTYLANE REFYNE 340
11.5.2.4 RESTYLANE KYSSE 340
11.5.2.5 RESTYLANE CONTOUR 340
11.5.3 BELOTERO BALANCE 341
11.5.4 REVANESSE VERSA 341
11.5.5 RHA 341
11.5.5.1 RHA 2 341
11.5.5.2 RHA 3 341
11.5.5.3 RHA 4 341
11.5.6 HYLAFORM 341
11.5.7 ELEVESS 341
11.5.8 PREVELLE SILK 341
11.5.9 OTHERS 341
11.6 SCAR TREATMENT 342
11.6.1 ACNE SCARS 343
11.6.2 HYPERTROPHIC SCARS 343
11.6.3 KELOID SCARS 343
11.6.4 CONTRACTURE SCARS 343
11.6.5 OTHERS 344
11.6.6 JUVEDERM 344
11.6.7 RESTYLANE 344
11.6.8 RADIESSE 344
11.6.9 BELOTERO 344
11.6.10 PERLANE 344
11.6.11 OTHERS 344
11.7 SAGGING SKIN 345
11.7.1 BOLETERO 346
11.7.2 RESTYLANE 346
11.7.3 JUVEDERM 346
11.7.4 OTHERS 346
11.8 CHEEK DEPRESSION 346
11.8.1 JUVEDERM VOLUMA 347
11.8.2 RESTYLANE-LYFT 347
11.8.3 SCULPTRA 347
11.8.4 RADIESSE 347
11.8.5 OTHERS 347
11.9 RECONSTRUCTIVE SURGERY 348
11.9.1 JUVEDERM 349
11.9.2 RESTYLANE 349
11.9.3 OTHERS 349
11.10 AESTHETIC RESTORATION 349
11.10.1 JUVEDERM 350
11.10.1.1 JUVEDERM ULTRA XC 351
11.10.1.2 JUVEDERM VOLBELLA XC 351
11.10.1.3 JUVEDERM VOLLURE XC 351
11.10.2 RESTYLANE 351
11.10.2.1 RESTYLANE LYFT 351
11.10.2.2 RESTYLANE-L 351
11.10.2.3 RESTYLANE REFYNE AND DEFYNE 351
11.10.2.4 RESTYLANE SILK 351
11.10.3 SCULPTRA 351
11.10.4 RADIESSE 351
11.10.5 RHA 352
11.10.5.1 RHA 2 352
11.10.5.2 RHA 3 352
11.10.5.3 RHA 4 352
11.10.6 REVANESSE VERSA 352
11.10.7 BELOTERO BALANCE 352
11.10.8 BELLAFILL 352
11.10.9 OTHERS 352
11.11 DENTISTRY 353
11.11.1 JUVEDERM 354
11.11.2 RESTYLANE 354
11.11.3 RADIESSE 354
11.11.4 OTHERS 354
11.12 CHIN AUGMENTATION 354
11.12.1 JUVEDERM VOLUMA XC 355
11.12.2 RESTYLANE DEFYNE 355
11.12.3 OTHERS 355
11.13 LIPOATROPHY TREATMENT 356
11.13.1 SCULPTRA 356
11.13.2 OTHERS 356
11.14 SKIN SMOOTHING 357
11.14.1 RESTYLANE 358
11.14.2 BELOTERO 358
11.14.3 BELLAFIL 358
11.14.4 OTHERS 358
11.15 EARLOBE REJUVENATION 358
11.15.1 SCULPTRA 359
11.15.2 RESTYLANE 359
11.15.3 ELLANSE 359
11.15.4 BELOTERO 359
11.15.5 JUVEDERM 359
11.15.6 OTHERS 359
11.16 OTHERS 360
12 EUROPE AESTHETIC INJECTABLE FILLERS MARKET, BY END USER 361
12.1 OVERVIEW 362
12.2 DERMATOLOGY CLINICS 365
12.3 HOSPITALS 366
12.4 AMBULATORY SURGICAL CENTERS 367
12.5 OTHERS 368
13 EUROPE AESTHETIC INJECTABLE FILLERS MARKET, BY DISTRIBUTION CHANNEL 369
13.1 OVERVIEW 370
13.2 DIRECT TENDER/DIRECT DISTRIBUTION 373
13.3 DRUG STORES 374
13.4 ONLINE PHARMACY 375
13.5 OTHERS 376
14 EUROPE AESTHETIC INJECTABLE FILLERS MARKET, BY REGION 377
14.1 EUROPE 379
14.1.1 GERMANY 415
14.1.2 U.K. 449
14.1.3 ITALY 484
14.1.4 SPAIN 518
14.1.5 FRANCE 552
14.1.6 SWITZERLAND 586
14.1.7 NETHERLANDS 620
14.1.8 BELGIUM 653
14.1.9 AUSTRIA 687
14.1.10 DENMARK 720
14.1.11 SWEDEN 753
14.1.12 NORWAY 787
14.1.13 FINLAND 820
14.1.14 IRELAND 853
14.1.15 REST OF EUROPE 886
15 EUROPE AESTHETIC INJECTABLE FILLERS MARKET: COMPANY LANDSCAPE 887
15.1 COMPANY SHARE ANALYSIS: EUROPE 887
16 SWOT ANALYSIS 888
17 COMPANY PROFILE 889
17.1 ALLERGAN AESTHETICS 889
17.1.1 COMPANY SNAPSHOTS 889
17.1.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 890
17.1.3 COMPANY SHARE ANALYSIS 890
17.1.4 PRODUCT PORTFOLIO 890
17.1.5 RECENT DEVELOPMENT 892
17.2 GALDERMA 894
17.2.1 COMPANY SNAPSHOT 894
17.2.2 REVENUE ANALYSIS 894
17.2.3 COMPANY SHARE ANALYSIS 895
17.2.4 PRODUCT PORTFOLIO 895
17.2.5 RECENT DEVELOPMENT 897
17.3 MERZ PHARMA 898
17.3.1 COMPANY SNAPSHOT 898
17.3.2 COMPANY SHARE ANALYSIS 898
17.3.3 PRODUCT PORTFOLIO 899
17.3.4 RECENT DEVELOPMENT 900
17.4 HUGEL, INC. 901
17.4.1 COMPANY SNAPSHOT 901
17.4.2 REVENUE ANALYSIS 901
17.4.3 COMPANY SHARE ANALYSIS 902
17.4.4 PRODUCT PORTFOLIO 902
17.4.5 RECENT DEVELOPMENT 904
17.5 LG CHEM 905
17.5.1 COMPANY SNAPSHOT 905
17.5.2 REVENUE ANALYSIS 905
17.5.3 COMPANY SHARE ANALYSIS 906
17.5.4 PRODUCT PORTFOLIO 906
17.5.5 RECENT DEVELOPMENT 908
17.6 AMALIAN 909
17.6.1 COMPANY SNAPSHOT 909
17.6.2 PRODUCT PORTFOLIO 909
17.6.3 RECENT DEVELOPMENT 912
17.7 BIOSCIENCE 913
17.7.1 COMPANY SNAPSHOT 913
17.7.2 PRODUCT PORTFOLIO 913
17.7.3 RECENT DEVELOPMENT 915
17.8 BIOPLUS CO. LTD. 916
17.8.1 COMPANY SNAPSHOT 916
17.8.2 PRODUCT PORTFOLIO 916
17.8.3 RECENT DEVELOPMENT 919
17.9 BIOXIS PHARMACEUTICALS 920
17.9.1 COMPANY SNAPSHOT 920
17.9.2 PRODUCT PORTFOLIO 920
17.9.3 RECENT DEVELOPMENT 921
17.10 CONTURA INTERNATIONAL LTD 922
17.10.1 COMPANY SNAPSHOT 922
17.10.2 PRODUCT PORTFOLIO 922
17.10.3 RECENT DEVELOPMENT 923
17.11 CROMA-PHARMA GMBH 924
17.11.1 COMPANY SNAPSHOT 924
17.11.2 PRODUCT PORTFOLIO 924
17.11.3 RECENT DEVELOPMENT 925
17.12 HUONS GLOBAL 926
17.12.1 COMPANY SNAPSHOT 926
17.12.2 REVENUE ANALYSIS 926
17.12.3 PRODUCT PORTFOLIO 927
17.12.4 RECENT DEVELOPMENT 927
17.13 HUMEDIX 928
17.13.1 COMPANY SNAPSHOT 928
17.13.2 REVENUE ANALYSIS 928
17.13.3 PRODUCT PORTFOLIO 929
17.13.4 RECENT DEVELOPMENT 932
17.14 IBSA INSTITUT BIOCHIMIQUE SA 933
17.14.1 COMPANY SNAPSHOT 933
17.14.2 PRODUCT PORTFOLIO 933
17.14.3 RECENT DEVELOPMENT 935
17.15 JALUPRO 936
17.15.1 COMPANY SNAPSHOT 936
17.15.2 PRODUCT PORTFOLIO 936
17.15.3 RECENT DEVELOPMENT 937
17.16 LABORATORIES VIVACY 938
17.16.1 COMPANY SNAPSHOT 938
17.16.2 PRODUCT PORTFOLIO 938
17.16.3 RECENT DEVELOPMENT 941
17.17 LABORATORIES FILLMED 942
17.17.1 COMPANY SNAPSHOT 942
17.17.2 PRODUCT PORTFOLIO 942
17.17.3 RECENT DEVELOPMENT 943
17.18 MEDYTOX INC 944
17.18.1 COMPANY SNAPSHOT 944
17.18.2 REVENUE ANALYSIS 944
17.18.3 PRODUCT PORTFOLIO 945
17.18.4 RECENT DEVELOPMENT 948
17.19 MESOESTETIC 949
17.19.1 COMPANY SNAPSHOT 949
17.19.2 PRODUCT PORTFOLIO 949
17.19.3 RECENT DEVELOPMENT 951
17.20 PETRONE GROUP 952
17.20.1 COMPANY SNAPSHOT 952
17.20.2 PRODUCT PORTFOLIO 952
17.20.3 RECENT DEVELOPMENT 952
17.21 PREMIER MEDICAL GROUP 953
17.21.1 COMPANY SNAPSHOT 953
17.21.2 PRODUCT PORTFOLIO 953
17.21.3 RECENT DEVELOPMENT 954
17.22 PROLLENIUM MEDICAL TECHNOLOGIES 955
17.22.1 COMPANY SNAPSHOT 955
17.22.2 PRODUCT PORTFOLIO 955
17.22.3 RECENT DEVELOPMENT 957
17.23 REVANCE 958
17.23.1 COMPANY SNAPSHOT 958
17.23.2 PRODUCT PORTFOLIO 958
17.23.3 RECENT DEVELOPMENT 959
17.24 SINCLAIR 960
17.24.1 COMPANY SNAPSHOT 960
17.24.2 PRODUCT PORTFOLIO 960
17.24.3 RECENT DEVELOPMENT 964
17.25 SHANGHAI REYOUNGEL MEDICAL TECHNOLOGY COMPANY LIMITED 965
17.25.1 COMPANY SNAPSHOT 965
17.25.2 PRODUCT PORTFOLIO 965
17.25.3 RECENT DEVELOPMENT 968
17.26 SOSUM GLOBAL 969
17.26.1 COMPANY SNAPSHOT 969
17.26.2 PRODUCT PORTFOLIO 969
17.26.3 RECENT DEVELOPMENT 971
17.27 TIGER AESTHETICS MEDICAL, LLC 972
17.27.1 COMPANY SNAPSHOT 972
17.27.2 PRODUCT PORTFOLIO 972
17.27.3 RECENT DEVELOPMENT 973
17.28 TEOXANE 974
17.28.1 COMPANY SNAPSHOT 974
17.28.2 PRODUCT PORTFOLIO 974
17.28.3 RECENT DEVELOPMENT 975
17.29 VIDA SRL. 976
17.29.1 COMPANY SNAPSHOT 976
17.29.2 PRODUCT PORTFOLIO 976
17.29.3 RECENT DEVELOPMENT 977
17.30 ZHEJIANG JINGJIA MEDICAL TECHNOLOGY CO., LTD. 978
17.30.1 COMPANY SNAPSHOT 978
17.30.2 PRODUCT PORTFOLIO 978
17.30.3 RECENT DEVELOPMENT 979
18 QUESTIONNAIRE 980
19 RELATED REPORTS 984
?